NTRA - Natera, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
36.58
+1.41 (+4.01%)
At close: 4:00PM EST

36.58 0.00 (0.00%)
After hours: 4:07PM EST

Stock chart is not supported by your current browser
Previous Close35.17
Open34.96
Bid36.68 x 900
Ask36.57 x 800
Day's Range34.68 - 36.61
52 Week Range11.08 - 40.92
Volume636,350
Avg. Volume687,634
Market Cap2.8B
Beta (5Y Monthly)1.37
PE Ratio (TTM)N/A
EPS (TTM)-1.84
Earnings DateNov 6, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est42.50
  • Hedge Funds Have Never Been This Bullish On Natera Inc (NTRA)
    Insider Monkey

    Hedge Funds Have Never Been This Bullish On Natera Inc (NTRA)

    Like everyone else, elite investors make mistakes. Some of their top consensus picks, such as Amazon, Facebook and Alibaba, have not done well in Q4 of 2018 due to various reasons. Nevertheless, the data show elite investors' consensus picks have done well on average over the long-term. The top 20 stocks among hedge funds beat […]

  • Panorama Publication Demonstrates Utility of Measuring Individual Fetal Fractions in Twin Pregnancies
    PR Newswire

    Panorama Publication Demonstrates Utility of Measuring Individual Fetal Fractions in Twin Pregnancies

    Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced results of a study published in the Journal of Prenatal Diagnosis which demonstrated that measuring individual fetal fractions combined with reporting zygosity provides clinically powerful insights into the accuracy of the aneuploidy results.1 Panorama® remains the only non-invasive prenatal test (NIPT) that reports zygosity for twins, and individual fetal fractions for dizygotic pregnancies.2

  • What Kind Of Share Price Volatility Should You Expect For Natera, Inc. (NASDAQ:NTRA)?
    Simply Wall St.

    What Kind Of Share Price Volatility Should You Expect For Natera, Inc. (NASDAQ:NTRA)?

    If you're interested in Natera, Inc. (NASDAQ:NTRA), then you might want to consider its beta (a measure of share price...

  • Thomson Reuters StreetEvents

    Edited Transcript of NTRA earnings conference call or presentation 6-Nov-19 9:30pm GMT

    Q3 2019 Natera Inc Earnings Call

  • Natera (NTRA) Reports Q3 Loss, Tops Revenue Estimates
    Zacks

    Natera (NTRA) Reports Q3 Loss, Tops Revenue Estimates

    Natera (NTRA) delivered earnings and revenue surprises of 0.00% and 3.80%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Natera Reports Third Quarter 2019 Financial Results
    PR Newswire

    Natera Reports Third Quarter 2019 Financial Results

    SAN CARLOS, Calif. , Nov. 6, 2019 /PRNewswire/ -- Natera, Inc. (NASDAQ:  NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today reported financial results ...

  • Natera Announces Third Quarter 2019 Earnings Conference Call
    PR Newswire

    Natera Announces Third Quarter 2019 Earnings Conference Call

    SAN CARLOS, Calif. , Oct. 30, 2019 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it will release results for its third quarter ended September ...

  • Hedge Funds Are Betting On Natera Inc (NTRA)
    Insider Monkey

    Hedge Funds Are Betting On Natera Inc (NTRA)

    Based on the fact that hedge funds have collectively under-performed the market for several years, it would be easy to assume that their stock picks simply aren't very good. However, our research shows this not to be the case. In fact, when it comes to their very top picks collectively, they show a strong ability […]

  • Natera Announces Pricing of Follow-On Offering
    PR Newswire

    Natera Announces Pricing of Follow-On Offering

    SAN CARLOS, Calif. , Oct. 16, 2019 /PRNewswire/ --  Natera, Inc . (Nasdaq: NTRA), a global leader in cell-free DNA testing, today announced the pricing of its underwritten public offering of 5,714,286 ...

  • MarketWatch

    Natera stock falls after hours on secondary-offering announcement

    Natera Inc. shares fell in the extended session Tuesday after the DNA test company announced a secondary offering of its stock. Natera shares fell 6% after hours, following a 2.7% gain to close the regular session at $39.22. The company said it plans to offer $175 million in shares, with underwriters getting an option for $26.3 million to cover overallotments. J.P. Morgan, Morgan Stanley, Cowen, and Piper Jaffray are among the underwriters. At Tuesday's closing price, about 5.1 million shares will be offered, compared with about 70 million shares currently outstanding.

  • Natera Launches Proposed Follow-On Offering
    PR Newswire

    Natera Launches Proposed Follow-On Offering

    SAN CARLOS, Calif. , Oct. 15, 2019 /PRNewswire/ -- Natera, Inc . (Nasdaq: NTRA), a global leader in cell-free DNA testing, today announced the launch of a proposed follow-on public offering of $175,000,000 ...

  • Natera to Host Investor Conference Call to Discuss Progress in its Oncology Business
    PR Newswire

    Natera to Host Investor Conference Call to Discuss Progress in its Oncology Business

    SAN CARLOS, Calif. , Oct. 3, 2019 /PRNewswire/ -- Natera, Inc.  (NASDAQ: NTRA ), a global leader in cell-free DNA testing, today announced it will review recent progress in its oncology business, including ...

  • Natera (NTRA) Scales 52-Week High: What's Driving the Stock?
    Zacks

    Natera (NTRA) Scales 52-Week High: What's Driving the Stock?

    Natera (NTRA) is likely to maintain the current high on a number of favorable factors.

  • Foundation Medicine and Natera Partner to Advance Personalized Cancer Monitoring
    PR Newswire

    Foundation Medicine and Natera Partner to Advance Personalized Cancer Monitoring

    CAMBRIDGE, Mass. and SAN CARLOS, Calif., Sept. 25, 2019 /PRNewswire/ -- Foundation Medicine, Inc. and Natera, Inc. (NTRA) today announced a partnership to develop and commercialize personalized circulating tumor DNA (ctDNA) monitoring assays, for use by biopharmaceutical and clinical customers who order FoundationOne®CDx. "We are excited to develop monitoring products based on Foundation Medicine's genomic insights, and we believe that partnering with Natera, a leader in personalized ctDNA monitoring, offers the potential to significantly advance personalized medicine," said Cindy Perettie, Chief Executive Officer of Foundation Medicine. The companies will leverage Foundation Medicine's FoundationOne® CDx as the baseline test to define a set of unique variants that will subsequently be monitored utilizing a co-developed assay that includes components of Natera's Signatera™ platform.

  • PR Newswire

    CBR® Acquires Evercord™ Newborn Stem Cell Business from Natera

    LOS ANGELES , Sept. 13, 2019 /PRNewswire/ --  CBR (Cord Blood Registry), the world's largest newborn stem cell collection and storage company, today announced the asset acquisition of Natera, Inc. 's  (NASDAQ: ...

  • CBR to Acquire Natera's Evercord™ Cord Blood Business
    PR Newswire

    CBR to Acquire Natera's Evercord™ Cord Blood Business

    SAN CARLOS, Calif., Sept. 13, 2019 /PRNewswire/ -- Natera, Inc. (NTRA) and CBR (Cord Blood Registry) today announced the acquisition by CBR, a California Cryobank Life Sciences company, and the world's largest newborn stem cell collection and storage organization, of Natera's Evercord™ cord blood and tissue banking business. "This divestiture will allow Natera to focus squarely on its core genetic testing business in reproductive health, oncology and organ transplantation," said Steve Chapman, Natera's CEO.

  • Natera Publishes Largest NIPT Outcomes Study Demonstrating Robust Clinical Performance Over a 4-year Period
    PR Newswire

    Natera Publishes Largest NIPT Outcomes Study Demonstrating Robust Clinical Performance Over a 4-year Period

    SAN CARLOS, Calif., Sept. 9, 2019 /PRNewswire/ -- Natera, Inc. (NTRA), a global leader in cell-free DNA testing, today announced the publication of the largest non-invasive prenatal test (NIPT) outcomes study to date, analyzing its Panorama® assay over a 4-year period. The primary objective of the study, published in the Journal of Clinical Medicine,1 was to analyze prospectively the clinical performance of the company's NIPT as a part of its rigorous quality assurance program. Panorama now has a market-leading 19 peer-reviewed publications with 1.2 million patients, which is twice the number of patients in published studies from all other primary NIPT companies combined," said Ramesh Hariharan, General Manager of Natera's Reproductive Health business.

  • Did Natera, Inc. (NASDAQ:NTRA) Insiders Sell Shares?
    Simply Wall St.

    Did Natera, Inc. (NASDAQ:NTRA) Insiders Sell Shares?

    It is not uncommon to see companies perform well in the years after insiders buy shares. Unfortunately, there are also...

  • Natera to Present at the Morgan Stanley 17th Annual Global Healthcare Conference
    PR Newswire

    Natera to Present at the Morgan Stanley 17th Annual Global Healthcare Conference

    SAN CARLOS, Calif. , Sept. 4, 2019 /PRNewswire/ --  Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced it will webcast a live presentation at the Morgan Stanley 17th ...

  • Natera Appoints Rowan Chapman to its Board of Directors
    PR Newswire

    Natera Appoints Rowan Chapman to its Board of Directors

    SAN CARLOS, Calif., Aug. 29, 2019 /PRNewswire/ -- Natera, Inc. (NTRA), a global leader in cell-free DNA testing, has appointed Rowan Chapman, Ph.D., to its board of directors, effective August 15, 2019. "We are extremely pleased to welcome Dr. Rowan Chapman to our board and look forward to the valuable contribution she will provide," said Steve Chapman, Natera's Chief Executive Officer. Dr. Chapman is a founder, investor, and active independent board member.

  • Natera to Webcast Live Presentation at the Baird 2019 Global Healthcare Conference
    PR Newswire

    Natera to Webcast Live Presentation at the Baird 2019 Global Healthcare Conference

    SAN CARLOS, Calif. , Aug. 28, 2019 /PRNewswire/ -- Natera, Inc.  (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced it will webcast a live presentation at the Baird 2019 Global Healthcare ...

  • Medicare Issues Positive Draft Local Coverage Determination for Natera's Signatera™ MRD Test in Colorectal Cancer
    PR Newswire

    Medicare Issues Positive Draft Local Coverage Determination for Natera's Signatera™ MRD Test in Colorectal Cancer

    SAN CARLOS, Calif., Aug. 22, 2019 /PRNewswire/ -- Natera, Inc. (NTRA), a global leader in cell-free DNA testing, today announced that the Palmetto MolDX program has proposed a local coverage determination (LCD) for use of Natera's Signatera molecular residual disease (MRD) test in patients with certain forms of colorectal cancer (CRC). Patient stratification after surgical resection, where decisions regarding the need for chemotherapy will incorporate the presence or absence of residual disease as determined by Signatera.

  • Panorama NIPT Achieves 2 Million Test Milestone
    PR Newswire

    Panorama NIPT Achieves 2 Million Test Milestone

    SAN CARLOS, Calif., Aug. 22, 2019 /PRNewswire/ -- Natera, Inc. (NTRA), a global leader in cell-free DNA testing, today announced that it has now processed more than two million Panorama® non-invasive prenatal tests (NIPT). The Panorama test has been extensively validated in 18 peer-reviewed published­ clinical studies involving more than 170,000 patients. Additionally, Natera has funded the largest prospective NIPT trial ever conducted: the 20,000-patient SNP-based Microdeletion and Aneuploidy Registry Trial (SMART) study.

  • Thomson Reuters StreetEvents

    Edited Transcript of NTRA earnings conference call or presentation 7-Aug-19 8:30pm GMT

    Q2 2019 Natera Inc Earnings Call

  • GuruFocus.com

    Natera Inc (NTRA) CEO Steven Leonard Chapman Sold $3.3 million of Shares

    CEO of Natera Inc (30-Year Financial, Insider Trades) Steven Leonard Chapman (insider trades) sold 98,996 shares of NTRA on 08/09/2019 at an average price of $33 a share. Continue reading...